Systemic Lupus Erythematosus Clinical Trial
- Daily stress can worsens the clinical course of lupus.
- Objective: to determine the efficacy of the stress management therapy in a group of
patients with lupus.
- 45 patients with lupus and high daily stress participated in this clinical trial.
- Two groups resulted: a control group (CG) that received the usual care and a therapy
group (TG) that received a cognitive behavioral therapy.
- The therapy consisted of ten consecutive weekly sessions.
- The measured variables were psychological, clinical, immunological and quality of life.
At the basal moment and after 3, 9 and 15 months.
- Statistical analysis showed a significant reduction in the levels of depression,
anxiety and daily stress in the therapy group, compared to the usual care group, a
significant improvement in quality of life, improvements in the reported symptoms
(cardiovascular, respiratory, cutaneous and musculoskeletal.
Stress, especially daily stress, worsens the lupus symptoms perceived by the patients. Our
objective was to determine the efficacy of the Meichenbaum stress management therapy for
dealing with high daily stress in a group of patients with lupus.
We designed a randomized clinical trial in which 45 patients with lupus and daily stress
participated. The patients were randomly assigned to one of the following groups: a) a
control group (CG) that received the usual care and b) a therapy group (TG) that received a
cognitive behavioral type therapy, performed by a group of 3 psychologists. Both groups were
similar with regard to their sociodemographic, clinical, immunological, psychological
aspects at the basal moment. The therapy consisted of ten consecutive weekly sessions.
Psychological and emotional, clinical, immunological variables and quality of life were
evaluated at the basal moment and after 3, 9 and 15 months.
The between-groups analysis showed a significant reduction in the levels of depression,
anxiety and daily stress in the TG, compared to the CG, throughout the entire follow-up
period, as well as a significant improvement in quality of life. The results also showed
improvements in the reported symptoms (cardiovascular, respiratory, cutaneous and
musculoskeletal) in the patients from the TG, who showed significant differences with regard
to their basal level and in comparison with CG patients. This study shows the efficacy of
the Meichenbaum stress management therapy in patients with lupus and high daily stress, as
it significantly reduces the incidence of psychological disorders related to suffering from
lupus, and it significantly improves and maintains their quality of life, in spite of the
absence of a significant reduction in the illness activity index.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |